Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

HC Wainwright & Co. Maintains Neutral on Virios Therapeutics, Adjusts Price Target To $5 (25-1 Reverse Stock Split)

Author: Benzinga Newsdesk | October 09, 2024 02:24pm

HC Wainwright & Co. analyst Sean Lee maintains Virios Therapeutics (NASDAQ:VIRI) with a Neutral, adjusts target to $5 from $0.2 (25-1 Reverse Stock Split).

Posted In: VIRI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist